Circulating tumor DNA as an early cancer detection tool.
暂无分享,去创建一个
N. Schork | M. Murtaza | T. Slavin | R. Rockne | L. Goetz | S. Gray | A. Goel | J. Weitzel | P. Sahoo | Laura H. Goetz | Janet Mokhnatkin | Andrea Campos-Carrillo | Janet V Mokhnatkin | A. Goel
[1] David R. Jones,et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.
[2] S. Chin,et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer , 2019, Science Translational Medicine.
[3] H. Nielsen,et al. Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.
[4] Edith M. Ross,et al. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer , 2019, Cell reports.
[5] Alex Root,et al. Mathematical Modeling of The Challenge to Detect Pancreatic Adenocarcinoma Early with Biomarkers , 2019, Challenges.
[6] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[7] Sharyn I. Katz,et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.
[8] M. Speicher,et al. Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.
[9] Keval Patel,et al. Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.
[10] G. Sonpavde,et al. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. Diamandis,et al. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection , 2018, BMC Medicine.
[12] E. Diamandis,et al. Circulating Tumor DNA for Early Cancer Detection. , 2018, The journal of applied laboratory medicine.
[13] Benjamin Werner,et al. Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. , 2018, Cancer discovery.
[14] H. Ren,et al. Blood-based DNA Methylation Biomarkers for Early Detection of Colorectal Cancer , 2018, Journal of proteomics & bioinformatics.
[15] C. Paweletz,et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.
[16] Ludmila V. Danilova,et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.
[17] H. Ikeuchi,et al. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. , 2017, Gastroenterology.
[18] C. Gau,et al. Somatic TP53 variants frequently confound germline testing results , 2017, Genetics in Medicine.
[19] M. Plebanski,et al. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[20] Charles A Powell,et al. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement , 2017, American journal of respiratory and critical care medicine.
[21] G. Lyman,et al. Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology , 2017, JAMA oncology.
[22] Sharon S. Hori,et al. A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. , 2017, Cancer research.
[23] Ashwini Naik,et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.
[24] Mark Lee,et al. Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.
[25] M. Kerin,et al. Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer , 2017, Cancers.
[26] Y. Toiyama,et al. Diagnostic Potential of Cell-Free and Exosomal MicroRNAs in the Identification of Patients with High-Risk Colorectal Adenomas , 2016, PloS one.
[27] D. Bowtell,et al. Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. , 2016, Cancer research.
[28] Cheng Qian,et al. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer , 2016, Oncotarget.
[29] Jiong Wu,et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer , 2016, Oncotarget.
[30] Yongzhao Shao,et al. Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates , 2016, Scientific Reports.
[31] A. Torkamani,et al. Assessment of circulating copy number variant detection for cancer screening , 2016, bioRxiv.
[32] H. Burke. Predicting Clinical Outcomes Using Molecular Biomarkers , 2016, Biomarkers in cancer.
[33] A. Krainer,et al. Abstract PR11: Differentiation of mammary tumors and reduction in metastasis upon Malat1 LncRNA loss , 2016 .
[34] Carlos Caldas,et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.
[35] P. Neven,et al. Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. , 2015, JAMA oncology.
[36] M. Otsuka,et al. Circulating RNAs as new biomarkers for detecting pancreatic cancer. , 2015, World journal of gastroenterology.
[37] J. Garber,et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. , 2015, JAMA.
[38] G. Hannum,et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. , 2015, Clinical chemistry.
[39] A. Schetter,et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. , 2015, Journal of the National Cancer Institute.
[40] G. Nagaraju,et al. MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers , 2015, Tumor Biology.
[41] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[42] M. Genuardi,et al. MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria , 2014, Epigenetics.
[43] R. Grivell,et al. Noninvasive prenatal testing. , 2014, Australian family physician.
[44] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[46] Peiyong Jiang,et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing , 2013, Proceedings of the National Academy of Sciences.
[47] Y. Toiyama,et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.
[48] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[49] Sanjiv S Gambhir,et al. Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations , 2011, Science Translational Medicine.
[50] Hwee Tong Tan,et al. Serum autoantibodies as biomarkers for early cancer detection , 2009, The FEBS journal.
[51] X. Breakefield,et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer , 2009, British Journal of Cancer.
[52] Sanjiv S Gambhir,et al. Cancer Screening: A Mathematical Model Relating Secreted Blood Biomarker Levels to Tumor Sizes , 2008, PLoS medicine.
[53] William E. Grizzle,et al. Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.
[54] F. F. Madrid,et al. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. , 2005 .
[55] J. Chin,et al. Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis , 2005 .
[56] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[57] V A Memoli,et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[58] P Mandel,et al. Les acides nucleiques du plasma sanguin chez l' homme , 1948 .